Rubius Therapeutics News Releases https://ir.rubiustx.com/ Rubius Therapeutics News Releases en Rubius Therapeutics Announces Issuance of Multiple U.S. Patents for its Red Cell Therapeutic Programs https://ir.rubiustx.com/news-releases/news-release-details/rubius-therapeutics-announces-issuance-multiple-us-patents-its First U.S. Composition of Matter Patent Issued for Genetically Engineered Red Cell CAMBRIDGE, Mass. , June 05, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely Wed, 05 Jun 2019 08:00:00 -0400 Rubius Therapeutics News Releases 7151 Rubius Therapeutics to Present at Jefferies 2019 Healthcare Conference https://ir.rubiustx.com/news-releases/news-release-details/rubius-therapeutics-present-jefferies-2019-healthcare-conference CAMBRIDGE, Mass. , May 28, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics , Inc. (Nasdaq:RUBY),  a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, announced today that Pablo J. Tue, 28 May 2019 16:05:00 -0400 Rubius Therapeutics News Releases 7101 Rubius Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress https://ir.rubiustx.com/news-releases/news-release-details/rubius-therapeutics-reports-first-quarter-2019-financial-results Enrollment for Phase 1b Trial of RTX-134 for Phenylketonuria on Track for Second Quarter 2019; Initial Clinical Data Anticipated in Second Half 2019 Company Announces Transition of President Torben Straight Nissen , Ph.D. CAMBRIDGE, Mass. , May 15, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. Wed, 15 May 2019 08:00:00 -0400 Rubius Therapeutics News Releases 7066 Rubius Therapeutics to Announce First Quarter 2019 Financial Results https://ir.rubiustx.com/news-releases/news-release-details/rubius-therapeutics-announce-first-quarter-2019-financial CAMBRIDGE, Mass. , May 06, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced plans to report first quarter 2019 Mon, 06 May 2019 16:05:00 -0400 Rubius Therapeutics News Releases 7056 Rubius Therapeutics to Participate in Jefferies 6th Annual IO Cell Therapy Summit https://ir.rubiustx.com/news-releases/news-release-details/rubius-therapeutics-participate-jefferies-6th-annual-io-cell CAMBRIDGE, Mass. , April 03, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics , Inc. (Nasdaq:RUBY),  a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, announced today that Torben Straight Nissen , Wed, 03 Apr 2019 16:05:00 -0400 Rubius Therapeutics News Releases 7021 Rubius Therapeutics Announces Extensive Preclinical Data for Three Red Cell Therapeutic Oncology Programs at the 2019 American Association for Cancer Research Annual Meeting https://ir.rubiustx.com/news-releases/news-release-details/rubius-therapeutics-announces-extensive-preclinical-data-three CAMBRIDGE, Mass. , April 02, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced that the company presented Tue, 02 Apr 2019 08:00:00 -0400 Rubius Therapeutics News Releases 7006 Rubius Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results with Business Updates https://ir.rubiustx.com/news-releases/news-release-details/rubius-therapeutics-reports-fourth-quarter-and-full-year-2018 Investigational New Drug Application Cleared for First-Ever Red Cell Therapeutic™, RTX-134, for Treatment of Phenylketonuria Data from Company’s Oncology Pipeline to be Presented at AACR 2019 Annual Meeting CAMBRIDGE, Mass. , March 28, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. Thu, 28 Mar 2019 08:00:00 -0400 Rubius Therapeutics News Releases 6981 Rubius Therapeutics Appoints Natalie Holles to its Board of Directors and Greg Whitehead as Senior Vice President and Chief Quality Officer https://ir.rubiustx.com/news-releases/news-release-details/rubius-therapeutics-appoints-natalie-holles-its-board-directors CAMBRIDGE, Mass. , March 25, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced the appointment of Natalie Holles , Mon, 25 Mar 2019 08:00:00 -0400 Rubius Therapeutics News Releases 6966 Rubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial Results https://ir.rubiustx.com/news-releases/news-release-details/rubius-therapeutics-announce-fourth-quarter-and-full-year-2018 CAMBRIDGE, Mass. , March 19, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced plans to report fourth quarter and Tue, 19 Mar 2019 16:05:00 -0400 Rubius Therapeutics News Releases 6956 Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria https://ir.rubiustx.com/news-releases/news-release-details/rubius-therapeutics-announces-fda-clearance-investigational-new CAMBRIDGE, Mass. , March 11, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced that the U.S. Mon, 11 Mar 2019 04:00:00 -0400 Rubius Therapeutics News Releases 6941